Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · April 14, 2022

Outcomes Associated With SLN360 Administered at Different Doses in Patients With Elevated Lp(a) Levels

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels
JAMA 2022 Apr 03;[EPub Ahead of Print], SE Nissen, K Wolski, C Balog, DI Swerdlow, AC Scrimgeour, C Rambaran, RJ Wilson, M Boyce, KK Ray, L Cho, GF Watts, M Koren, T Turner, ES Stroes, C Melgaard, GV Campion

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading